{"prompt": "['Product: MK-3475', '16', 'Protocol/Amendment No.: 604-09', 'investigator decision to withdraw the subject, noncompliance, or', 'administrative reasons requiring cessation of treatment.', 'Subjects who experience documented progressive disease (PD)', 'verified by blinded independent central review will have the option', 'to remain on study and continue receiving the originally assigned', 'trial treatment for a total of 35 cycles at the discretion of the', 'investigator (Section 7.1.5.5).', 'Subjects who stop trial treatment after receiving 35 administrations', 'of trial treatment for reasons other than PD or intolerability may be', 'eligible for the Second Course Phase, up to 17 additional', 'administrations of pembrolizumab (approximately 1 year), upon', 'experiencing disease progression (Section 7.1.5.4). Subjects in the', 'saline placebo arm are not eligible for the Second Course Phase.', 'After the end of treatment, each subject will be followed for the', 'occurrence of AEs and spontaneously reported pregnancy', '(Section 7.2).', 'Subjects who discontinue for reasons other than PD will have', 'post-treatment follow-up for disease status until experiencing PD', 'confirmed by the site per immune-related Response Evaluation', 'Criteria in Solid Tumors (irRECIST) or per RECIST version 1.1', '(modified to follow a maximum of 10 target lesions and a maximum', 'of 5 target lesions per organ) as assessed by BICR, initiating a non-', 'study cancer treatment, withdrawing consent, or becoming lost to', 'follow-up. All subjects will be followed by telephone for overall', 'survival until death, withdrawal of consent, or the end of the study.', 'Randomization Ratio', '1:1', 'A list of abbreviations used in this document can be found in Section 12.6.', '2.0 TRIAL DESIGN', '2.1', 'Trial Design', 'This is a worldwide, randomized, placebo-controlled, Phase 3, parallel group, multi-site,', 'double-blind trial of pembrolizumab plus standard of care (SOC) chemotherapy (EP) in', 'subjects with ES-SCLC who have not previously received systemic therapy for this', 'malignancy.', 'Approximately 430 subjects will be randomized (1:1) to either pembrolizumab + EP or', 'placebo + EP. Randomization will be stratified by type of platinum therapy (cisplatin or', 'carboplatin), Eastern Cooperative Oncology Group (ECOG) performance status score', '(0 or 1), and lactate dehydrogenase (LDH) measurement (< or > upper limit of normal', '[ULN]) at baseline. Positive tumor programmed cell death-ligand 1 (PD-L1) expression will', \"not be required for enrollment; however, subjects' tumors will be screened for PD-L1\", 'expression. An overview of the trial design is depicted in Figure 1.', 'Prior to randomization, the investigator will determine whether the subject will receive', 'cisplatin or carboplatin. Subjects are allowed to switch from cisplatin to carboplatin if the', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '17', 'Protocol/Amendment No.: 604-09', 'subject develops an adverse event (AE), becomes ineligible for further cisplatin therapy,', 'and/or the investigator considers switching to carboplatin to be in the best interest of the', 'subject.', 'During the Treatment Phase, subjects will have a study visit every 3 weeks (Q3W) for', 'assessments and trial treatment administration. In Cycles 1 to 4, subjects will receive the', 'SOC treatment component (EP) along with either pembrolizumab 200 mg or placebo.', 'Subjects in either treatment arm who achieve a partial response (PR) or complete response', '(CR) at the completion of Cycle 4 may be offered prophylactic cranial irradiation (PCI) at the', 'discretion of the investigator (Section 7.1.2.6). Treatment with PCI should begin within 2 to', '4 weeks (no later than 6 weeks) after the last trial treatment in Cycle 4. Trial treatment may', 'continue during PCI; however, if it is necessary to suspend trial treatment, it must be', 'restarted no later than 2 weeks after completion of PCI. Subjects will continue to receive', 'treatment with pembrolizumab or placebo Q3W for up to an additional 31 cycles (up to', '35 cycles total) or until occurrence of one or more treatment discontinuation criteria: disease', 'progression as assessed by blinded independent central review (BICR) confirmed per', 'Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) (modified to', 'follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ),', 'intolerable toxicity or unacceptable AEs, intercurrent illness that prevents further', 'administration of treatment, investigator decision to withdraw the subject, noncompliance', 'with trial treatment or procedure requirements, or administrative reasons requiring cessation', 'of treatment.', 'After randomization, subjects will be evaluated with radiographic imaging to assess response', 'to treatment; treatment-based decisions should be made by the investigator based on', 'immune-related RECIST (irRECIST) (Section 4.2.3.5). All imaging obtained on study will', 'be submitted for BICR using RECIST 1.1 for verification of progressive disease (PD) and for', 'determination of objective response rate (ORR) and progression-free survival (PFS). Adverse', 'event monitoring will be ongoing throughout the trial and AEs will be graded for severity', 'according to the guidelines outlined in the National Cancer Institute (NCI) Common', 'Terminology Criteria for Adverse Events version 4.0 (CTCAE 4.0).', 'After verification of PD as assessed by BICR per RECIST 1.1 (modified to follow a', 'maximum of 10 target lesions and a maximum of 5 target lesions per organ), subjects will', 'have the option to remain on study and continue receiving the originally assigned trial', 'treatment for a total of 35 cycles at the discretion of the investigator, provided they are', 'deemed to be benefiting and are clinically stable (Section 7.1.2.7.6). Alternatively, subjects', 'may choose to receive treatment with an appropriate second-line (2L) therapy as determined', 'by the investigator.', 'At the discretion of the investigator and in consultation with the Sponsor, subjects assigned', 'to the pembrolizumab arm who complete 35 treatment administrations may be eligible for', 'retreatment with open-label pembrolizumab monotherapy at the time of radiographic disease', 'progression (verified by BICR), provided that no other systemic therapy for SCLC has been', 'administered. This retreatment is called the Second Course Phase (Section 6.2 and', 'Section 7.1.5.5). Subjects in the saline placebo arm are not eligible for the Second Course', 'Phase. Treatment assignment will be unblinded for those subjects who meet all criteria for', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}